. 2020 Jul 10;27(9):2251–2260. doi: 10.1016/j.sjbs.2020.07.011

Table 4.

Effect of Doxorubicin (DOX) and different treatments of AHE on serum protein, albumin, globulin, BUN, serum nitrite profile.

Treatment (mg/kg)	Serum proteins (mg/dl)	Albumin (mg/dl)	Globulin (mg/dl)	BUN (mg/dl)	Serum nitrite (µM/ml)
Control	78.06 ± 0.361^b	19.70 ± 0.889^b	58.36 ± 1.246^b	9.167 ± 0.033^b	41.50 ± 0.764^b
DOX	37.95 ± 0.396^a	9.367 ± 0.73^a	28.59 ± 1.115^a	23.17 ± 0.561^a	82.37 ± 0.797^a
AHE alone	79.06 ± 0.554^b	19.93 ± 0.636^b	59.12 ± 1.078^b	9.133 ± 0.033^b	41.20 ± 0.611^b
DOX + AHE (200)	52.19 ± 0.384^a,b,d	15.23 ± 0.176^a**,b	36.95 ± 0.40^a,b,d	17.07 ± 0.23^a,b,d	62.67 ± 0.921^a,b,d
DOX + AHE (400)	73.32 ± 0.439^a,b,c	17.78 ± 0.174^b	55.54 ± 0.425^b,c	12.53 ± 0.484^a,b,c	48.13 ± 0.962^a,b,c
DOX + Sily	74.62 ± 0.50^a**,b	17.87 ± 0.233^b	56.75 ± 0.333^b	12.37 ± 0.367^a,b	47.23 ± 0.535^a**,b

Values expressed as mean ± SEM. a: Significance at p < 0.0001 Vs. control group, b: Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^**: Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin.